Portable infusion pumps in ambulatory cancer chemotherapy

Fifty‐seven adult patients receiving chemotherapy were treated with a total of 133 infusions using portable user‐worn infusion pumps, the Autosyringe AS*2F, Cormed ML6–4, and two earlier versions of the latter, the Sigmamotor ML6–2 and ML6–3. Ninety‐eight infusions were given on an ambulatory basis. Fourteen infusions were given through peripheral venous catheters, 115 through central venous catheters, and four intra‐arterially. Of 127 evaluable infusions, 65 were completed within 5% and 87 within 10% of the planned rate; results are similar for both inpatient and outpatient infusions. The Cormed ML6–4 pumps was equal to the Autosyringe AS*2F in reliability but superior to the latter in patient preference. There were no instances of dangerously rapid administration of the drug. The only serious catheter complications were a pneumothorax after insertion of a subclavian catheter in one patient and cellulitis in a leukopenic patient with a Broviac catheter. All but three patients preferred outpatient therapy to hospitalization. Outpatient therapy costs about $300 per day less than in‐hospital treatment.